Assay Development for Heat Shock Proteins

A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery

Volumn , Issue , 2009, Pages 83-97

  Gao, Zhenhai ^a   Fong, Susan ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77749326874     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420070514-10     Document Type: Chapter

References (29)

1. Agatsuma, T. et al. 2002. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg. Med. Chem. 10, 3445-3454.
2. Brune, M. et al. 1998. Mechanism of inorganic phosphate interaction with phosphate binding protein from Escherichia coli. Biochemistry 37, 10370-10380.
3. Chiosis, G., Huezo, H. et al. 2003. 17AAG: low target binding affinity and potent cell activity: finding an explanation. Mol. Cancer Ther. 2, 123-129.
4. Chiosis, G., Lucas, B. et al. 2003. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets 3, 371-376.
5. Du, Y. et al. 2007. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. J. Biomol. Screen. 12, 915-924.
6. Fortugno, P. et al. 2003. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 100, 13791-13796.
7. Goetz, M.P. et al. 2003. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann. Oncol. 14, 1169-1176.
8. Howes, R. et al. 2006. A fluorescence polarization assay for inhibitors of Hsp90. Anal. Biochem. 350, 202-213.
9. Kamal, A., M.F. Boehm, and F.J. Burrows. 2004. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 10, 283-290.
10. Kamal, A. et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410.
11. Kim, J. et al. 2004. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomol. Screen. 9, 375-381.
12. Kwon, H.J. et al. 1992. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 52, 6926-6930.
13. Marcu, M.G. et al. 2000. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275, 37181-37186.
14. Maroney, A.C. et al. 2006. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 45, 5678-5685.
15. McLaughlin, S.H., H.W. Smith, and S.E. Jackson. 2002. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J. Mol. Biol. 315, 787-798.
16. Owen, B.A. et al. 2002. Regulation of heat shock protein 90 ATPase activity by sequences in the carboxyl terminus. J. Biol. Chem. 277, 7086-7091.
17. Pacey, S. et al. 2006. Hsp90 inhibitors in the clinic. Handb. Exp. Pharmacol. 172, 331-358.
18. Panaretou, B. et al. 2002. Activation of the ATPase activity of hsp90 by the stress-regulated co-chaperone aha1. Mol. Cell 10, 1307-1318.
19. Pearl, L.H. 2005. Hsp90 and Cdc37: a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 15, 55-61.
20. Pratt, W.B. and D.O. Toft. 2003. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228, 111-133.
21. Rowlands, M.G. et al. 2004. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. 327, 176-183.
22. Sausville, E.A., J.E. Tomaszewski, and P. Ivy. 2003. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 3, 377-383.
23. Soldano, K.L. et al. 2003. Structure of the N-terminal domain of GRP94: basis for ligand specificity and regulation. J. Biol. Chem. 278, 48330-48338.
24. Sreedhar, A.S. et al. 2004. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 562, 11-15.
25. Suriawinata, A. 2004. Survivin: apoptosis inhibitor and its regulation by Hsp90. Lab. Invest. 84, 395-403.
26. Whitesell, L. et al. 1994. Inhibition of heat shock protein 90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91, 8324-8328.
27. Workman, P. 2004. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 10, 47-51.
28. Workman, P. et al. 2007. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad. Sci. 1113, 202-216.
29. Zhou, V. et al. 2004. A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal. Biochem. 331, 349-357.